The 340B Rebate Model is set to be implemented in 2027, while the Inflation Reduction Act (IRA) introduces the Maximum Fair Price (MFP) for ten Medicare Part D drugs, which takes effect on January 1, 2026.
These significant changes present considerable operational challenges for Covered Entities.
To address these transitions, Tungsten+PLUS™ is designed to support the new 340B Rebate Model, facilitate the implementation of the Maximum Fair Price, and improve Dispute Automation to effectively manage the challenges of the 340B program that all stakeholders encounter.
DaysDays
HrsHours
MinsMinutes
SecsSeconds
We use cookies to analyze website traffic and optimize your website experience.